Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women

Fertility and Sterility

Volumn 88, Issue 6, 2007, Pages 1645-1652

  Seifer, David B ^a   Golub, Elizabeth T ^b   Lambert Messerlian, Geralyn ^c   Springer, Gayle ^b   Holman, Susan ^d   Moxley, Michael ^e   Cejtin, Helen ^f   Nathwani, Niyati ^g   Anastos, Kathryn ^h   Minkoff, Howard ^d   Greenblatt, Ruth M ⁱ  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c BROWN UNIVERSITY   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f Jr Hospital of Cook County   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h MONTEFIORE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV; M llerian inhibiting substance; ovarian reserve

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; FOLLITROPIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR;

ADULT; AGING; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; FOLLICULAR PHASE; GENITAL SYSTEM; HORMONE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION; MULTIVARIATE ANALYSIS; OVARY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGING; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICULAR PHASE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; OVARY; PROSPECTIVE STUDIES; REPRODUCTION;

EID: 36749015719     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.01.122     Document Type: Article

References (33)

1. Seifer D.B., MacLaughlin D.T., Christian B.P., Feng B., and Shelden R.M. Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 77 (2002) 468-471
2. de Vet A., Laven J.S.E., de Jong F.H., Themmen A.P.N., and Fauser B.C.J.M. Anti-Mullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77 (2002) 357-362
3. van Rooij I.A., Broekmans F.J., te Velde E.R., Fauser B.C., Bancsi L.F., Jong F.H., et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17 (2002) 3065-3071
4. van Rooij I.A.J., Broekmans F.J.M., Scheffer G.J., Looman C.W.N., Habbema J.D.F., de Jong F.H., et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83 (2005) 979-987
5. Fanchin R., Schonauer L.M., Righini C., Guibourdenche J., Frydman R., and Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18 (2003) 323-327
6. Hazout A., Bouchard P., Seifer D.B., Aussage P., Junca A.M., and Cohen-Bacrie P. Serum anti-mullerian hormone/mullerian inhibiting substance appears to be a more discriminatory marker of ART outcome than follicular stimulating hormone, inhibin B or estradiol. Fertil Steril 82 (2004) 1323-1329
7. van Rooij I.A.J., Tonkelaar I., Broekmans F.J., Looman C.W.N., Scheffer G.J., de Jon F.H., et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11 (2004) 601-606
8. Tremellen K.P., Kolo M., Gilmore A., and Lekamge D.N. Anti-mullerian hormone as a marker of ovarian reserve. Aust NZ J Obstet Gynaecol 45 (2005) 20-24
9. Ficicioglu C., Kutlu T., Baglam E., and Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 85 (2006) 592-596
10. Visser J.A., de Jong F.H., Laven J.S., and Themmen A.P. Anti-mullerian hormone: a new marker for ovarian function. Reproduction 131 (2006) 1-9
11. Ebner T., Sommergruber M., Moser M., Shebl O., Schreier-Lechner E., and Tews G. Basal level anti-mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 21 (2006) 2022-2026
12. Creinin M.D. Laboratory criteria for menopause in women using oral contraceptives. Fertil Steril 66 (1996) 101-104
13. Henrich J.B., Hughes J.P., Kaufman S.C., Brody D.J., and Curtin L.R. Limitations of follicle-stimulating hormone in assessing menopause status: findings from the National Health and Nutrition Examination Survey (NHANES 1999-2000). Menopause 13 (2006) 171-177
14. Backer L.C., Rubin C.S., Marcus M., Kieszak S.M., and Schober S.E. Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994). Menopause 6 (1999) 29-35
15. Danforth D.R., Arbogast L.K., Mroueh J., Kim M.H., Kennard E.A., Seifer D.B., et al. Dimeric Inhibin: a direct marker of ovarian aging. Fertil Steril 70 (1998) 119-123
16. Welt C.K., McNicholl D.J., Taylor A.E., and Hall J.E. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 84 (1999) 105-111
17. Seifer D.B., Scott Jr. R.T., Bergh P.A., Abrogast L.K., Friedman C.I., Mack C.K., et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil Steril 72 (1999) 63-65
18. Freeman E.W., Sammel M.D., Gracia C.R., Kapoor S., Lin H., Liu L., et al. Follicular phase hormone levels and menstrual bleeding status in the approach to menopause. Fertil Steril 83 (2005) 383-392
19. Miller S.A., Santoro N., Lo Y., Howard A.A., Arnsten J.H., Floris-Moore M., et al. Menopause symptoms in HIV-infected and drug-using women. Menopause 12 (2005) 348-356
20. Fantry L.E., Zhan M., Taylor G.H., Sill A.M., and Flaws J.A. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDS 19 (2005) 703-711
21. Schoenbaum E.E., Hartel D., Lo Y., Howard A.A., Floris-Moore M., Arnsten J.H., et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 41 (2005) 1517-1524
22. Santoro N., Arnsten J.H., Buono D., Howard A.A., and Schoenbaum E.E. Impact of street drug use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-aged women. J Womens Health (Larchmt) 14 (2005) 898-905
23. Harlow S.D., Cohen M., Ohmit S.E., Schuman P., Cu-Uvin S., Lin X., et al. Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol 188 (2003) 881-886
24. Harlow S.D., Schuman P., Cohen M., Ohmit S.E., Cu-Uvin S., Lin X., et al. Effect of HIV infection on menstrual cycle length. J Acquir Immune Defic Syndr 24 (2000) 68-75
25. Cejtin H.E., Kalinowski A., Bacchetti P., Taylor R.N., Watts D.H., Kim S., et al. Effects of Human Immunodeficiency Virus on protracted amenorrhea and ovarian dysfunction. Obstet Gynecol 108 (2006) 1423-1431
26. Barkan S.E., Melnick S.L., Martin-Preston S., Weber K., Kalish L.A., Miotti P., et al. The Women's Interagency HIV Study. Epidemiology 9 (1998) 117-125
27. Bacon M.C., von Wyl V., Alden C., Sharp G., Robison E., Hessol N., et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 12 (2005) 1013-1019
28. Cook C.L., Siow Y., Taylor S., and Fallat M.E. Serum mullerian inhibiting substance levels during normal menstrual cycles. Fertil Steril 73 (2000) 859-861
29. La Marca A., Malmusi S., Giulini S., Tamaro L.F., Orvieto R., Levaratti P., et al. Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19 (2004) 2738-2741
30. Fanchin R., Taieb J., Mendez Lozano D.H., and Ducot B. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum Reprod 20 (2005) 923-927
31. Fanchin R., Schonauer L.M., Righini C., Frydman N., Frydman R., and Taieb J. Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod 18 (2003) 328-332
32. La Marca A., Giulini S., Orvieto R., De Leo V., and Volpe A. Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 20 (2005) 1569-1572
33. La Marca A., Giulini S., Tirelli A., Bertucci E., Marsella T., Xella S., et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22 (2007) 766-771